^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ifebemtinib (IN10018)

    i
    Other names: IN10018, BI-853520, N10018
    Company:
    Boehringer Ingelheim, InxMed
    Drug class:
    FAK inhibitor
    Related drugs:
    3ms
    Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling. (PubMed, Biomark Res)
    Our study demonstrates that the combination of IN10018 and crizotinib shows synergistic antitumor effects in TNBC. Mechanistically, this combination inhibits cell proliferation, enhances apoptosis, and induces ferroptosis, which is associated with increased p53 levels.
    Journal • PARP Biomarker • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • GPX4 (Glutathione Peroxidase 4) • CASP9 (Caspase 9) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    ROS1 expression
    |
    Xalkori (crizotinib) • ifebemtinib (IN10018)
    4ms
    a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (clinicaltrials.gov)
    P1/2, N=140, Recruiting, InxMed (Shanghai) Co., Ltd. | Enrolling by invitation --> Recruiting
    Enrollment status • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    4ms
    IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov)
    P1, N=120, Recruiting, InxMed (Shanghai) Co., Ltd. | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)
    5ms
    a Phase Ib/II Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (clinicaltrials.gov)
    P1/2, N=140, Enrolling by invitation, InxMed (Shanghai) Co., Ltd.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    6ms
    IN10018 Combination Therapy in Treatment-naïve ES-SCLC (clinicaltrials.gov)
    P1/2, N=120, Recruiting, InxMed (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    carboplatin • Tevimbra (tislelizumab) • etoposide IV • ifebemtinib (IN10018)
    7ms
    Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Recruiting, InventisBio Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    8ms
    IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=168, Recruiting, InxMed (Shanghai) Co., Ltd.
    New P2 trial • Combination therapy
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin • ifebemtinib (IN10018)
    over1year
    IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov)
    P1, N=120, Recruiting, InxMed (Shanghai) Co., Ltd. | N=52 --> 120 | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)
    over1year
    Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Not yet recruiting, InventisBio Co., Ltd | Initiation date: Jun 2022 --> Sep 2022
    Trial initiation date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    almost2years
    Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Not yet recruiting, InventisBio Co., Ltd
    New P1/2 trial • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    3years
    Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. (PubMed, Cancer Biol Med)
    In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT...FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone (P < 0.01). These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    ifebemtinib (IN10018)